I'm Interested
Study: An Open-label, Dose Escalation and Expansion, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors
Please Select Your Affiliation with CU Anschutz

Thank you for expressing your interest in a research study and for taking the time to provide your information.

By clicking 'Submit', your information will be shared with the research team. Typically a member of the research team will contact you within 3 to 5 business days.

Please understand that:

  • The research team will need to determine whether you are eligible for the study. Clicking 'Submit' does not enroll you into the study, or guarantee that you qualify for the study.
  • It is always your choice to participate.

Thanks again. Volunteers such as yourself are at the core of our work.